


Westminster Health Forum policy conference:

Next steps for AI use in life sciences

Timing: Morning, Tuesday, 14th July 2026

Taking Place Online



WESTMINSTER
HEALTH FORUM

Draft agenda subject to change

- 8.30 Registration
- 9.00 **Chair's opening remarks**
Senior Parliamentarian
- 9.05 **Assessing the National Commission's recommendations on AI regulation in healthcare**
Professor Alastair Denniston, Chair, UK National Commission on the Regulation of AI in Healthcare
Questions and comments from the floor
- 9.30 **Addressing barriers to AI in life sciences - data access, responsible use, and risk mitigation**
data consistency, quality and interoperability | alignment of datasets for use in AI research and development | AI-ready data infrastructure and the role of the HDRS | access models, timelines and cost considerations for SMEs and academic teams | risk management, including hallucinations, bias, and data misuse | standards for synthetic data and RAG systems | AI assurance and validation mechanisms | maintaining patient safety and trust | consent frameworks, public engagement, and ethical standards
Taly Dvorkis, Director, Fieldfisher
Susheel Varma, Chief Data Officer, Sage Bionetworks
Dr Jeffry Hogg, Clinical Innovation Officer, AI and Clinical Scientist, University Hospitals Birmingham NHS Foundation Trust
Senior representative, SME
Senior representative, public engagement
Questions and comments from the floor
- 10.20 **Regulatory pathways for accelerating safe adoption of AI in life sciences - insights from the AI Airlock sandbox**
Dr MiRa Jacobs, Head, Digital Health, Innovative Devices Team, and Agency Lead, AI Airlock, Medicines and Healthcare products Regulatory Agency
Questions and comments from the floor
- 10.45 **Chair's closing remarks**
Senior Parliamentarian
- 10.50 Break
- 11.00 **Chair's opening remarks**
Senior Parliamentarian
- 11.05 **Key considerations for scaling up and adoption of AI in research and drug discovery**
transition from trials to broader deployment | digital integration and evidence standards to support evaluation and wider access | future use of bespoke IT solutions | regulator, industry, and research collaboration | governance frameworks for clinical and research deployment | workforce development | clinical capability, adoption readiness, and sustainable deployment | defining minimum standards for clinical deployment | clarifying allocation of liability across clinical contexts | ongoing monitoring and real-world evaluation | reliability of AI ambient scribes and AI as a medical device
Senior representative, research
Senior representative, industry
Questions and comments from the floor
- 11.40 **International pathways for accelerating access to breakthrough technologies**
Junaid Bajwa, Senior Partner, Head, UK, and Science Partner, Pioneering Intelligence, Flagship Pioneering
- 11.50 **Priorities for investment, commercialisation and market access**
stage-specific investment requirements | establishing clear pathways for commercial adoption | improving regulatory predictability to support investment decisions | Regulatory Innovation Corridor priorities | entry points and eligibility | achieving regulatory coherence | alignment with UKRI AI Research and Innovation Strategic Framework priorities | managing uncertainty around commercial outcomes and system performance | procurement approaches | assessing data readiness gaps | opportunities for cross-border collaboration | reimbursement and procurement barriers
Dr Kristin-Anne Rutter, Executive Director, Cambridge University Health Partners
Senior representative, investment
Senior representative, NHS trust
- 12.05 Questions and comments from the floor
- 12.30 **Next steps for AI and life sciences**
Senior representative, healthcare policy
Questions and comments from the floor
- 12.55 **Chair's and Westminster Health Forum closing remarks**
Senior Parliamentarian
Jessica Lear, Westminster Health Forum